Literature DB >> 32953340

A Case of Seronegative ANA Hydralazine-Induced Lupus Presenting With Pericardial Effusion and Pleural Effusion.

Karim O Elkholy1, Hamza Akhtar1, Abishek Chakraborti1.   

Abstract

Hydralazine induced lupus syndrome (HILS), a form of Drug-Induced Lupus (DIL), was first reported in 1953. Since then, studies have shown an increasing incidence of HILS. It presents with lupus-like symptoms such as arthralgia, fever, chest pain, anorexia, fatigue, petechiae, and rash. Though rare, HILS may initially present with pericardial effusion. Lab findings of HILS usually show positive anti-nuclear antibody (ANA) in >95% of cases, antihistone abs in >95% of cases, rheumatoid factor ab in 20%, and anti-double-strand DNA in <5%. Herein we present a case of HILS which initially presented with a seronegative ANA and pericardial effusion. An 82-year-old woman who presented with shortness of breath was found to have bilateral pleural effusion and pericardial effusion. Common etiologies of pericardial effusion have been ruled out, after careful review of her home medications, hydralazine was suspected to be the culprit of her pericardial effusion. Initial ANA testing was negative, however given high clinical suspicion autoimmune disease screening was done revealing positive anti-histone antibodies. Hydralazine was deemed to be the etiology of her pericardial effusion which led to the discontinuation of the drug. Serial echocardiography revealed no recurrence of the effusion.
Copyright © 2020, Elkholy et al.

Entities:  

Keywords:  ana; anti-histone; drug induced lupus; hydralazine; hydralazine induced lupus; negative ana; pericardial effusion; pericardiocentesis; pleural effusion; transthoracic echocardiography

Year:  2020        PMID: 32953340      PMCID: PMC7495962          DOI: 10.7759/cureus.9831

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  14 in total

1.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

Review 2.  Drug-induced lupus. The list of culprits grows.

Authors:  M W Rich
Journal:  Postgrad Med       Date:  1996-09       Impact factor: 3.840

Review 3.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

4.  Antinuclear antibody-negative, drug-induced lupus caused by lisinopril.

Authors:  J D Carter; J Valeriano-Marcet; K S Kanik; F B Vasey
Journal:  South Med J       Date:  2001-11       Impact factor: 0.954

5.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

6.  Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy.

Authors:  D J REINHARDT; J M WALDRON
Journal:  J Am Med Assoc       Date:  1954-08-21

Review 7.  Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.

Authors:  Shannon W Finks; A Lloyd Finks; Timothy H Self
Journal:  South Med J       Date:  2006-01       Impact factor: 0.954

8.  Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling.

Authors:  Chun Deng; Qianjin Lu; Zhiyong Zhang; Tharaknath Rao; John Attwood; Raymond Yung; Bruce Richardson
Journal:  Arthritis Rheum       Date:  2003-03

9.  ANA-Negative Hydralazine-Induced Pericardial Effusion.

Authors:  Vicken Zeitjian; Azar Mehdizadeh
Journal:  Case Rep Med       Date:  2017-12-17

10.  Antinuclear antibody-negative lupus? An ominous presentation of hydralazine-induced lupus syndrome.

Authors:  Theodros Solomon-Tsegaye; Edward L Treadwell; Reginald Obi; Mariavittoria Pitzalis
Journal:  Eur J Rheumatol       Date:  2018-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.